Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02313454 · ClinicalTrials.gov registry record · NA
Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye
A NA study, sponsored by Allergan.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02313454 is a NA study that has completed, run by Allergan. The registered enrollment target is 21 participants.
The verdict
NCT02313454, a NA study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye exacerbated by the Controlled Adverse Environment (CAE) Model.
Interventions
- DEVICE Intranasal Tear Neurostimulator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2014-11-17 |
| Est. Completion | 2015-04-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02313454
The ClinicalTrials.gov registry entry for NCT02313454 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intranasal Tear Neurostimulator is the first listed.
NCT02313454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02313454 about?
NCT02313454 is a clinical study titled "Evaluation of the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Patients With Dry Eye". The purpose of this study was to evaluate the safety and effectiveness of the Intranasal Tear Neurostimulator applied intranasally compared with the same device applied extranasally (control) in treating the symptoms of dry eye exacerbated by the Controlled Adverse Environment (CAE) Model.
What is the current status of trial NCT02313454?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2014-11-17. Estimated completion is 2015-04-08.
What interventions are being tested in trial NCT02313454?
The interventions under investigation include: Intranasal Tear Neurostimulator (DEVICE).
Who is sponsoring clinical trial NCT02313454?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.